PRAGUE (Reuters) – Novavax Inc plans to register approval for its COVID-19 candidate vaccine in the United States in December, executive Chairman Stanley Erck said in an interview with Czech Hospodarske Noviny, published Thursday.
The company plans to produce a component of the vaccine at its Czech plant, which will allow the country to obtain the product once it is approved, according to the journal quoted through Erck.
Novavax said Monday that he had begun recruiting volunteers by the time of an ongoing clinical trial of his COVID-19 vaccine candidate, with provisional knowledge expected by the fourth quarter of 2020.
Reporting through Jan Lopatka
All quotes were delayed for at least 15 minutes. See here for a complete list of operations and delays.
© 2020 Reuters. All rights are reserved.